BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sangesland M, Lingwood D. Antibody Focusing to Conserved Sites of Vulnerability: The Immunological Pathways for 'Universal' Influenza Vaccines. Vaccines (Basel) 2021;9:125. [PMID: 33562627 DOI: 10.3390/vaccines9020125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Pacheco GA, Gálvez NMS, Soto JA, Andrade CA, Kalergis AM. Bacterial and Viral Coinfections with the Human Respiratory Syncytial Virus. Microorganisms 2021;9:1293. [PMID: 34199284 DOI: 10.3390/microorganisms9061293] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Ronsard L, Yousif AS, Peabody J, Okonkwo V, Devant P, Mogus AT, Barnes RM, Rohrer D, Lonberg N, Peabody D, Chackerian B, Lingwood D. Engineering an Antibody V Gene-Selective Vaccine. Front Immunol 2021;12:730471. [PMID: 34566992 DOI: 10.3389/fimmu.2021.730471] [Reference Citation Analysis]
3 Roubidoux EK, Schultz-Cherry S. Animal Models Utilized for the Development of Influenza Virus Vaccines. Vaccines (Basel) 2021;9:787. [PMID: 34358203 DOI: 10.3390/vaccines9070787] [Reference Citation Analysis]
4 Zhu X, Han J, Sun W, Puente-Massaguer E, Yu W, Palese P, Krammer F, Ward AB, Wilson IA. Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface. Proc Natl Acad Sci U S A 2022;119:e2200821119. [PMID: 35594401 DOI: 10.1073/pnas.2200821119] [Reference Citation Analysis]
5 Houser KV, Chen GL, Carter C, Crank MC, Nguyen TA, Burgos Florez MC, Berkowitz NM, Mendoza F, Hendel CS, Gordon IJ, Coates EE, Vazquez S, Stein J, Case CL, Lawlor H, Carlton K, Gaudinski MR, Strom L, Hofstetter AR, Liang CJ, Narpala S, Hatcher C, Gillespie RA, Creanga A, Kanekiyo M, Raab JE, Andrews SF, Zhang Y, Yang ES, Wang L, Leung K, Kong WP, Freyn AW, Nachbagauer R, Palese P, Bailer RT, McDermott AB, Koup RA, Gall JG, Arnold F, Mascola JR, Graham BS, Ledgerwood JE; VRC 316 Study Team. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat Med 2022. [PMID: 35115706 DOI: 10.1038/s41591-021-01660-8] [Reference Citation Analysis]
6 Sangesland M, Lingwood D. Public Immunity: Evolutionary Spandrels for Pathway-Amplifying Protective Antibodies. Front Immunol 2021;12:708882. [PMID: 34956170 DOI: 10.3389/fimmu.2021.708882] [Reference Citation Analysis]
7 Wijesundara DK, Williams C, Sun W, Furuya AM, Furuya Y. Fear of Influenza Resurgence amid COVID-19 Pandemic: Need for Effective Flu Vaccine Still Exists. Vaccines (Basel) 2021;9:1198. [PMID: 34696304 DOI: 10.3390/vaccines9101198] [Reference Citation Analysis]